Experts agree more care should be given to cardiovascular safety concerns during clinical cancer trials. The Cardiovascular Safety Research Consortium published new recommendations for addressing those concerns Dec. 10 in JACC: CardioOncology.
Here are five notes from the recommendations:
- The update includes refinement of definitions, reporting terms and grading for cardiovascular adverse events.
- Event adjudication is recommended for complex or rare cardiovascular events such as myocarditis to improve accuracy in classification.
- Trial sites should be educated on recognizing and correctly reporting cardiovascular events. Baseline tests should be used to identify potential adverse events earlier.
- Data collection should be standardized to ensure consistent reporting across trial sites and promote accurate assessment of clinical outcomes.
- Trial sites are encouraged to collaborate with cardiologists as evidence of cancer therapies' effect on cardiovascular health grows.
Read the full recommendations here.